Latest / Investor Exchange / Lonza Group Half-Year 2025 Results

Transcript

Lonza Group Half-Year 2025 Results · Investor Exchange

• 0:02
  Time for another Investor Exchange podcast. Here are your hosts, Matt and Sally.
• 0:07
  Have you ever stopped to think, you know, what really powers the big pharma
• 0:11
  companies, especially the ones focused on making the medicines of tomorrow?
• 0:17
  Right. It's more than just the science, isn't it? Exactly. It's not just about
• 0:20
  those lab breakthroughs.
• 0:21
  Underneath it all, there's this huge engine of, well, financial performance
• 0:26
  that keeps everything running.
• 0:27
  Absolutely crucial. So today we're doing a deep dive into Lonza's half-year 2025 results.
• 0:34
  Lonza, as you probably know, is a really key global player in biotech and pharma
• 0:40
  manufacturing. A major CDMO partner.
• 0:42
  Our mission here is to kind of cut through the usual dense financial reports,
• 0:47
  you know, all the detailed analysis.
• 0:48
  At the core of it. Yes. You want to pull out the key numbers,
• 0:51
  really understand what drove their performance, the good stuff,
• 0:55
  and maybe the not so good stuff.
• 0:56
  The highs and the lows. And figure out the strategic outlook for them.
• 1:00
  We've got the insights straight from Lanz's own half-year report 2025 brochure and their APM brochure.
• 1:06
  That's Alternative Performance Measures. Good sources.
• 1:09
  Direct from the company. Okay, let's unpack this then. Dive into the numbers
• 1:13
  that really tell the story. Let's do it.
• 1:14
  So looking at the big picture, Lanz's first half of 2025, the headline figures,
• 1:20
  they look pretty strong, actually. They do.
• 1:22
  Group sales reported at CHF 3.6 billion. And what really jumped out at me was
• 1:27
  the growth, almost 20% growth, when you adjust for currency changes.
• 1:31
  That's the CER growth, yeah.
• 1:33
  19.0%, very solid. And their core EBITDA, that key profit measure,
• 1:38
  hit CHF 1.1 billion, margin holding steady near 30%.
• 1:42
  29.6% margin, up slightly actually, plus 0.4 percentage points versus last year.
• 1:48
  Okay, but we just threw out terms like constant exchange rate, CER, and core EBITDA.
• 1:53
  For listeners trying to follow these reports, what do those actually mean?
• 1:56
  Why are they important? That's a great question because they're not just jargon. They're about clarity.
• 2:00
  Constant exchange rate, CER, it's basically a way to take currency swings out of the equation.
• 2:05
  Right, because Lanza operates globally. Exactly. Swiss franc versus the dollar,
• 2:10
  the euro, those rates change all the time and can make sales look higher or
• 2:14
  lower than they really are in terms of business volume.
• 2:16
  So CER shows the underlying operational growth. Precisely.
• 2:19
  It calculates this year's sales using last year's exchange rates.
• 2:23
  So you see how much the business grew just from, you know, selling more stuff, not from currency luck.
• 2:28
  Okay, that makes sense. And core results, like core EBITDA.
• 2:32
  Similar idea, aiming for a cleaner year-on-year comparison.
• 2:37
  Lanza uses core figures to exclude what they call exceptional items.
• 2:41
  Like one-offs. Yeah, things that aren't part of the regular day-to-day business,
• 2:45
  big restructuring costs, maybe environmental remediation from old sites,
• 2:49
  or costs from major transformation projects. Things you wouldn't expect every year.
• 2:54
  Right. So taking those out, the core numbers give you a more consistent view
• 2:58
  of the fundamental ongoing performance.
• 3:00
  You can gauge the operational health without those temporary bumps or dips.
• 3:04
  Got it. That distinction is really helpful for seeing the real pulse of the operations.
• 3:08
  It cuts through the noise. Definitely. And speaking of operations,
• 3:11
  Lanza's CDMO, Business Contract Development and Manufacturing Organization,
• 3:15
  that really stands out here, doesn't it?
• 3:17
  Oh, absolutely. That's their core, helping other companies make drugs.
• 3:21
  It delivered CHF $3.1 billion in sales with even stronger CER growth, 23.1%.
• 3:28
  And the core EBITDA margin held firm at 30.2%.
• 3:33
  Pretty much flat margin compared to H1 2024, despite that strong growth,
• 3:37
  which is impressive in itself. The report mentions sustained commercial momentum
• 3:42
  and high utilization levels in mammalian small-scale assets as key drivers.
• 3:47
  What does that tell you, that high utilization and momentum?
• 3:51
  Well, it tells us they're firing on all cylinders in a really hot area.
• 3:54
  High utilization means their factories, their manufacturing lines,
• 3:58
  are running close to full capacity.
• 4:00
  Which is good for profits. Fantastic for profits. You're maximizing the return
• 4:04
  on those very expensive facilities.
• 4:06
  And sustained commercial momentum means they keep winning new business and keeping
• 4:10
  existing clients happy.
• 4:12
  So they're a go-to partner. Looks like it. It signals they're a preferred partner
• 4:15
  in the CDMO world. And holding that margin steady while growing sales so fast,
• 4:20
  that points to really good cost control and efficient scaling.
• 4:23
  They're digging their competitive moat deeper, especially in biologics.
• 4:26
  Right, becoming indispensable.
• 4:28
  Okay, so that strong CDMO performance sets the stage.
• 4:31
  And Lonza actually simplified its structure recently, right?
• 4:35
  April 1st this year. Yeah, a new operating model.
• 4:38
  Three CDMO platforms now. Integrative biologics, advanced synthesis,
• 4:42
  specialized modalities. plus the capsules and health ingredients business, CHI.
• 4:47
  And that new structure helps us drill down a bit, see where the action is.
• 4:50
  Exactly. Pinpoint the drivers. So let's start with what sounds like the main
• 4:54
  engine, integrated biologics.
• 4:56
  This segment showed, wow, really strong CER sales growth, 39.3%. Huge number.
• 5:02
  And the core EBITDA margin was also very healthy at 36.0%. What was behind that kind of power?
• 5:08
  It looks like a combination of things working well. The Vacaville site acquisition
• 5:12
  definitely gave them a big sales boost, adding much needed capacity. So M&A played a role.
• 5:17
  Yes, but it wasn't just that. The report says there was sustained high demand
• 5:21
  for both their large-scale and small-scale assets in Biologics.
• 5:25
  People want what they make. Seems so.
• 5:27
  And crucially, they mention good operational execution and their growth projects maturing.
• 5:33
  That means the investments they've been making are coming online and actually
• 5:36
  performing well. Like the Vacaville site, performing better than expected on margin.
• 5:40
  Right. So it's not just buying growth, it's executing well on it.
• 5:44
  It shows their strategy in biologics is paying off, strengthening their position.
• 5:49
  That's a really good sign, that execution piece.
• 5:52
  Okay, moving to advanced synthesis. Also strong expansion here,
• 5:56
  CERR sales growth of 18.3%.
• 5:59
  Still very solid growth. But the really eye-catching thing here is the core
• 6:02
  EBITDA margin jumped up to 40.3%. That's nearly seven percentage points higher.
• 6:08
  What was the magic there? Well, the report points to strong contributions from
• 6:11
  both small molecules and bioconjugates within that segment.
• 6:15
  A big factor was the ramp up of their growth project, so new capacity or capabilities
• 6:19
  contributing more. Investments paying off again. Exactly.
• 6:22
  And they mentioned operating leverage. That just means as sales grew,
• 6:26
  their fixed costs didn't rise as quickly, so more of that extra revenue dropped
• 6:30
  to the bottom line. Making more profit on each sale.
• 6:33
  Essentially, yes. And again, robust operational execution seems to be a theme.
• 6:39
  Good management and efficiency driving that significant profitability boost.
• 6:43
  Okay, so two segments showing really impressive momentum.
• 6:47
  But, you know, it's rarely all smooth sailing in a big company.
• 6:50
  Usually isn't. Specialized modalities, for example, face some notable headwinds.
• 6:54
  Its CER sales actually went down by 9.2 percent. Yeah, declined there.
• 6:59
  And the core EBITDA margin took a pretty big hit, too, down to 17.3 percent.
• 7:04
  What happened? What were the challenges hit in this specific segment? It's interesting.
• 7:08
  Their bioscience business within that segment actually grew OK.
• 7:11
  But that was more than wiped out by weaker performance in cell and gene therapy,
• 7:16
  CGT, and microbial. Why were those weaker?
• 7:18
  A couple of reasons cited. One is tough comparisons.
• 7:22
  H1 2024 was apparently very strong for CGT and microbial, so the year-on-year
• 7:26
  numbers look worse. High base effect. Right.
• 7:28
  But beyond that, they also mentioned pipeline variability in H1 2025.
• 7:33
  That suggests the flow of customer projects coming through wasn't as steady.
• 7:37
  Customer uncertainty, maybe.
• 7:38
  Could be. Plus, they flagged softer operational performance,
• 7:42
  specifically in CGT, and some kind of plant adaptation to microbial that temporarily
• 7:47
  affected output. So a mix of factors.
• 7:49
  Okay, so not one single thing. What's crucial, though, is how Lonza sees this, right?
• 7:54
  Are these temporary issues? That seems to be the message.
• 7:58
  They specifically say they anticipate a better second half for CGT and microbial
• 8:03
  with deliveries weighted towards Q4. That suggests they view these as manageable
• 8:08
  issues, not a fundamental breakdown.
• 8:10
  Right. That context is important. Is it a blip or a trend?
• 8:13
  They seem to think it's more of a blip. That's the read, yes.
• 8:16
  Okay. Lastly, let's touch on capsules and health ingredients, CHI.
• 8:20
  This business is described as being on a recovery path.
• 8:23
  Sales were flat on a CER basis, 0.0%, but the margin improved.
• 8:29
  Yeah, the core EBITDA margin climbed to 26.2%, up 1.4 percentage points.
• 8:34
  So what's driving that margin improvement, even with flat sales,
• 8:37
  and what are the signs it's really recovering?
• 8:40
  The margin improvement came mainly from higher production volumes,
• 8:42
  so they're making more, and the impact of productivity initiatives kicking in,
• 8:46
  getting more efficient.
• 8:47
  Okay. Any green shoots? Definitely some positive signs mentioned.
• 8:52
  The overall capsules business has apparently shown quarter-over-quarter CER
• 8:56
  sales growth since Q3 last year.
• 8:58
  That's a steady climb back. Good momentum. Yes. And the nutraceutical capsules
• 9:04
  part saw a good order momentum in the first half.
• 9:06
  Plus, they expect the pharma capsule side to get back to pre-COVID volumes later
• 9:11
  this year in H2. That would be significant. It would.
• 9:14
  And there's one more factor, some favorable preliminary rulings in U.S.
• 9:18
  Trade cases related to capsules.
• 9:19
  They expect that to help level the playing field in the U.S. market.
• 9:23
  Ah, so some external help potentially, too. Could be a nice tailwind for them.
• 9:27
  So yeah, looks like a slow but steady recovery underway for CHI.
• 9:31
  Resilience is the word they might use. Okay, so that covers the different business parts.
• 9:35
  Let's zoom out again and look at Lonza's overall financial health.
• 9:38
  Specifically cash flow and capital. Right, the money flows. Operational free
• 9:42
  cash flow, OFCF, before acquisitions and divestitures. That saw a pretty big drop.
• 9:47
  Came in at CHF 189 million, down from almost 300 million in H1 last year.
• 9:52
  Yeah, CHF 296 million was the H1 2024 number.
• 9:57
  Total OFCF was CHF 141 million, also down from 296 million.
• 10:02
  So first, remind us what OFCF actually measures, and second, why the big drop?
• 10:06
  Okay, OFCF is really important. It's the cash generated purely by the company's
• 10:11
  core business operations.
• 10:12
  Think of it as the cash left over before you account for financing or big investment activities.
• 10:17
  Cash to pay dividends or debt or buy things. Exactly. It shows the company's
• 10:21
  ability to fund those things from its own operations.
• 10:24
  Now, the decrease. Several things contributed. A big one was a negative change
• 10:29
  in operating networking capital.
• 10:31
  Meaning? Meaning more cash got tied up in day-to-day stuff like inventory sitting
• 10:34
  on shelves or waiting for customers to pay their bills. That was a negative
• 10:37
  CHF $415 million swing. Okay, that's significant. It is.
• 10:41
  Also, capital expenditures, CapEx, went up by 8.0% to CHF $672 million.
• 10:48
  That's money spent on new buildings, equipment, investing for the future.
• 10:52
  Fueling that growth we talked about. Precisely.
• 10:54
  And there's also a CHF $48 million impact from acquiring subsidiaries.
• 10:58
  So you add it all up. Less cash generated.
• 11:00
  But is it necessarily bad? Sounds like they're investing heavily.
• 11:03
  That's the key takeaway, I think. It's not necessarily a sign of operational
• 11:07
  weakness, but more of a strategic choice.
• 11:09
  They're using cash now to invest heavily in growth, especially CapEx,
• 11:14
  sacrificing some short-term cash flow for potentially bigger future returns. A trade-off.
• 11:19
  Common for growth companies. Very common. But definitely something you watch
• 11:23
  how quickly those investments start generating cash themselves.
• 11:26
  Makes sense. And related to that, their net debt went up, reached CHF $3,566
• 11:32
  million, up from about $2.9 billion at the end of 2024.
• 11:36
  Right, up from CHF $2,859 million.
• 11:39
  And the net debt to core EBITDA ratio ticked up too, from 1.5 to 1.7.
• 11:44
  What do these debt levels tell us? Should we be concerned? Well,
• 11:47
  these ratios basically measure financial leverage, how much debt the company
• 11:50
  carries relative to its earnings.
• 11:52
  So, yes, higher numbers mean more debt. But is 1.7 high?
• 11:55
  In the grand scheme, 1.7 times core EBITDA isn't usually considered dangerously
• 12:00
  high, especially for a company investing heavily like Lanza.
• 12:03
  If that debt is funding projects that will generate strong future earnings, it can be a smart move.
• 12:09
  Using debt strategically. Potentially, yes. We also have to remember they just
• 12:13
  completed a big CHF 2 billion share buyback program in March that uses cash
• 12:19
  and reduces equity, which can also push leverage ratios up. Right.
• 12:23
  And they canceled shares, too.
• 12:24
  Yes. A capital reduction in June. So there are multiple moving parts affecting
• 12:28
  these debt figures, operational investment, but also capital allocation choices like buybacks.
• 12:33
  Good context. OK, that brings us nicely to the road ahead.
• 12:36
  Lonza's outlook and their strategic direction. Where they're heading.
• 12:39
  Despite the cash flow dip and the challenges in one segment,
• 12:42
  they actually upgraded their outlook for the core CDMO business for the full year 2025.
• 12:48
  That caught my eye too. Pretty confident. They're now expecting CER sales growth
• 12:52
  of 20-21% for CDMO, up from approaching 20%.
• 12:56
  And the core EBITDA margin forecast is also up 30-31% now from approaching 30%.
• 13:01
  That's a strong signal, isn't it?
• 13:03
  Doubling down on the core business confidence. It absolutely is.
• 13:08
  Upgrading the outlook for that main growth engine suggests they really believe
• 13:12
  in the continued demand and their ability to execute.
• 13:15
  And it implies those specialized modalities issues are seen as contained,
• 13:19
  not derailing the overall CDMO train.
• 13:22
  Right. And they also confirm the outlook for the CHI business still expecting
• 13:27
  low to mid single digit CER sales growth and that improved margin in the mid 20s for the year.
• 13:34
  So a steady recovery expected there, too. Now, the strong focus on CDMO,
• 13:38
  especially with the upgrade, it raises that big strategic question about the CHI business.
• 13:43
  They said back in December they intended to exit CHI. Where does that stand?
• 13:47
  Still very much the plan, it seems.
• 13:49
  The report clarifies that as of June 30th, CHI wasn't technically available
• 13:53
  for immediate sale in its current state.
• 13:56
  Meaning, under accounting rules, they couldn't yet classify it as held for sale
• 14:00
  or discontinued operations.
• 14:02
  It takes time to prepare a business unit for sale or separation.
• 14:05
  But they're working on it.
• 14:06
  Yes. The report explicitly states they made good progress in H-1 2025 with the
• 14:12
  internal preparations to carve out and exit the CHI business.
• 14:15
  So the direction of travel is clear. Very clear. They're streamlining,
• 14:19
  focusing all their firepower on the core CDMO strengths.
• 14:22
  So what does this all mean for Lonza's future? Where are they really putting their chips?
• 14:27
  It really sounds like they're leaning hard into that mission statement,
• 14:30
  making the medicines of tomorrow. I think that's exactly right.
• 14:33
  The plan to exit CHI, combined with pouring investment into CDMO and upgrading
• 14:38
  its outlook, it points to a future Lonza that's a pure play powerhouse in contract
• 14:43
  development and manufacturing for pharma and biotech. Sharpening the focus. Absolutely.
• 14:47
  It allows them to concentrate resources, capital, management attention,
• 14:51
  everything on those high growth, high margin CDMO businesses that are genuinely
• 14:55
  enabling next generation therapies.
• 14:58
  It's a strategic bet on their core competence.
• 15:01
  Doubling down on what they do best to support that innovation.
• 15:03
  Precisely. Cementing their role as a critical partner in life sciences.
• 15:07
  So there you have it. A look inside Lonza's half-year 2025.
• 15:12
  A company showing strong performance overall, really driven by that core CDMO
• 15:18
  business, especially integrated biologics and advanced synthesis.
• 15:22
  Despite a few bumps in specialized modalities. Right. Which they seem confident about managing.
• 15:27
  And the CHI business is on that steady recovery path as the company prepares to eventually exit it.
• 15:33
  Hopeful this deep dive gives you a much more nuanced picture than just the headlines.
• 15:37
  Getting behind the numbers, understanding the why.
• 15:40
  Exactly. Seeing the drivers, the challenges, and the strategic thinking behind
• 15:43
  a company like Lonza's moves. How will they plan to win in the future?
• 15:46
  So here's something for you, the listener, to think about.
• 15:49
  What really stands out to you about Lonza's strategy here, particularly that
• 15:53
  decision to eventually exit the CHI business?
• 15:56
  How do you think that move might shape their identity and their role in making
• 15:59
  the medicines of tomorrow in the years ahead.